US2022033769A1PendingUtilityA1

Bioreactor System

Assignee: KIYATEC INCPriority: Mar 15, 2013Filed: Oct 15, 2021Published: Feb 3, 2022
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
G01N 33/5014C12N 5/0068C12M 29/10C12M 23/44C12N 5/0693C12M 35/08C12N 2533/80C12M 29/04C12N 2533/30C12N 2513/00C12N 5/0062G01N 33/5011C12N 5/0695G01N 2500/10G01N 33/5073G01N 2333/904
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A three dimensional cell culture and bioreactor system is provided. The system comprises one or more cell culture chamber. Each cell culture chamber comprises an inlet port and an outlet port in fluid communication with the cell culture chamber. The cell culture chambers may be segregated or in fluid communication with one another. The systems may be used to conduct drug efficacy test, isolate certain cell types from a complex tissue sample of multiple cell types, allow for the ex vivo culturing of patient tissue samples to help guide the course of treatment, and conduct co-culture experiments.

Claims

exact text as granted — not AI-modified
1 - 29 . (canceled) 
     
     
         30 . A three dimensional cell culture and bioreactor system comprising:
 a cell culture chamber comprising an inlet port and an outlet port that are in communication with an interior volume of the cell culture chamber, wherein the interior volume of the cell culture chamber is configured to house a target cell population; and   a cell-scaffold construct housed in the cell culture chamber, wherein the scaffold portion of the cell-scaffold construct is made from a combination of a porous stiff culture material having a modulus greater than 1 GPa and a soft material having a modulus of less than 500 MPa, wherein the porous stiff culture material has a pore size ranging from 400 micrometers to 2 millimeters.

Join the waitlist — get patent alerts

Track US2022033769A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.